News
The completion of this study could positively impact AstraZeneca’s stock performance by enhancing investor confidence in their oncology pipeline. As the company continues to innovate in cancer ...
Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is ...
The Pension Fund Regulatory and Development Authority has published 40 vacancies for the recruitment of Officer Grade ‘A’ ...
Marvel has finally remembered how to make a movie again like its Phase 1 films with The Fantastic Four: First Steps.
Quantum Biopharma Ltd. (NASDAQ:QNTM) announced on Tuesday that its subsidiary Huge Biopharma Australia has received the ...
Led by a team of African researchers, first doses of the novel T cell-inducing GRAdHIVNE1 vaccine candidate have been given.
The MRT-8102 Phase 1 study is a randomized, double-blind, placebo-controlled trial in healthy volunteers that includes both single ascending dose (SAD) and multiple ascending dose (MAD) cohorts.
Phase 2 of the voting closes at noon ET on July 2, with starting lineups for each league announced on July 6 at 5 PM ET on ESPN. For now, let's dig into the Phase 1 voting results.
2d
WTEN Albany on MSNAlbany International Airport completes phase 1 of concourse upgradesThe Albany International Airport has completed the first phase of its Concourse A Rehabilitation Project. Phase one included ...
U.S. President Donald Trump has directed federal agencies to assess China's performance under the Phase 1 trade deal that he signed with Beijing in 2020 during his first term at the White House.
Biogen Inc. announced positive interim results from a Phase 1 study of salanersen (BIIB115/ION306), a novel antisense oligonucleotide for treating spinal muscular atrophy (SMA). The data show that ...
Based on the preliminary Phase 1 safety results, a safety review committee comprising study staff and independent physicians concluded the compound was well tolerated by participants. Martin Low, CEO ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results